Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 203-208 , 15 February 2003

Mitoxantrone in progressive multiple sclerosis: when and how to treat?

  • R.E Gonsette

      Affiliations

    • Corresponding Author InformationTel.: +32-2-752-96-22; fax: +32-2-752-97-00.

References 

  1. Jain KK. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin. Investig. Drugs. 2000;9:1139–1149
  2. The Multiple Sclerosis Study Group . Efficacy and toxicity of Cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. Ann. Neurol. 1990;27:591–605
  3. Goodkin DE, Rudick RA, Vanderbrug Medendorp S, et al.  Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 1995;37:30–40
  4. Ellison GW, Meyers LW, Mickey MR, et al.  A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis. Neurology. 1989;39:1018–1026
  5. Cook SD, Devereux C, Troiano R, et al.  Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet. 1986;8495:1405–1408
  6. Goodkin DE, Plencner S, Palmer-Saxerud J, Teetzen M, Hertsgaard D. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs. nonmaintenance therapy. Arch. Neurol. 1987;44:823–827
  7. Ehninger G, Proksch B, Heinzel G, Woodward DL. Clinical pharmacology of mitoxantrone. Cancer Treat. Rep. 1986;70:1373–1378
  8. Fidler J, Smith F, Gibbons J. Mitoxantrone inhibits helper function and enhances suppressor activity. Agents Actions. 1985;16:607–608
  9. Levine S, Gherson J. Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int. J. Immunopharmacol. 1986;8:999–1007
  10. Fidler JM, Quinn DeJoy S, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone: I. Suppression of B lymphocyte function. J. Immunol. 1986;137:727–732
  11. Mustafa M, Diener P, Sun JB, Link H, Olsson T. Immunopharmacologic modulation of experimental allergic encephalomyelitis: low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell mediated myelin-directed autoimmunity. Scand. J. Immunol. 1993;38:499–507
  12. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL. Suppression of demyelination by mitoxantrone. Int. J. Immunopharmacol. 1991;13:923–930
  13. Fidler JM, Quinn DeJoy S, Smith FR, Gibbons JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone: II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J. Immunol. 1986;136:2747–2754
  14. Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS. Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol. Immunopathol. 1985;35:35–42
  15. Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J. Neuroimmunol. 1986;13:175–181
  16. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 1987;45:122–128
  17. Bisteau M, Devos G, Brucher JM, Gonsette RE. Prevention of subacute experimental allergic encephalomyelitis in guinea-pigs with desferriowamine, isoprinosine and mitoxantrone. In:  Gonsette RE,  Delmotte P editor. Recent advances in multiple sclerosis therapy. Amsterdam: Elsevier; 1989;p. 299–300
  18. Gonsette RE, Demonty L. Mitoxantrone: a new immunosuppressive agent in multiple sclerosis. In:  Gonsette RE,  Delmotte P editor. Recent advances in multiple sclerosis therapy. Amsterdam: Elsevier; 1989;p. 161–164
  19. Gonsette RE, Demonty L. Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology. 1990;40(Suppl. 1):261; [537P]
  20. Mauch E, Kornhuber HH. Die immunsuppressive Therapie der multiplen Sklerose mit Mitoxantron. Fortschr. Neurol. Psychiatr. 1993;61:410–417
  21. Kappos L, Gold R, Künstler E, et al.  Mitoxantrone (Mx) in the treatment of rapidly progressive MS: a pilot study with serial gadolinium (Gd)-enhanced MRI. Neurology. 1990;40(Suppl. 1):261; [539P]
  22. Noseworthy JH, Lee D, Penman M, et al.  A phase II evaluation of mitoxantrone HCl in the treatment of progressive multiple sclerosis. Neurology. 1991;41(Suppl. 1):146; [122P]
  23. Krapf H, Mauch E, Fetzer U, Laufen H, Kornhuber HH. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology. 1995;37:113–139
  24. Edan G, Miller D, Clanet M, et al.  Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J. Neurol. Neurosurg. Psychiatry. 1997;62:112–118
  25. Millefiorini E, Gasperini C, Pozzilli C, et al.  Randomized placebo-controlled trial of mitoxantrone in relapsing–remitting multiple sclerosis: 24-month clinical and MRI outcome. J. Neurol. 1997;244:153–159
  26. MIMS-Study Group Hartung HP, Gonsette R. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomized observer-blind phase III trial: clinical results and three-year follow-up. Neurology. 1999;52(Suppl. 2):A290; [S45.005]
  27. MIMS-Study Group Hartung HP, Gonsette R. Mitoxantrone in progressive multiple sclerosis (MS): clinical results and three-year follow-up of the MIMS-trial. Ectrims 99 Mult. Scler. 1999;5(Suppl. 1):S15; [56]
  28. Hartung H.P., Gonsette R.E., Konig N., Kwiecinski A., Guseo A., Morrissey S., et al. and the MIMS Study Group, A phase III placebo-controlled, double-blind randomised, multicenter trial of mitoxantrone in progressive multiple sclerosis. Lancet (in press).
  29. Gonsette RE. Mitoxantrone immunotherapy in multiple sclerosis. Mult. Scler. 1996;1:329–332
  30. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, et al.  The natural history of multiple sclerosis: a geographically based study: I. Clinical course and disability. Brain. 1989;112:133–146
  31. Noseworthy JH, Hopkins MB, Vandervoort MK, et al.  An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology. 1993;43:1401–1406
  32. La Mantia L, Eoli M, Salmaggi A, Torri V, Milanese C. Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital. J. Neurol. Sci. 1998;19:32–36
  33. Shenkenberg TD, Von Hoff DD. Possible mitoxantrone-induced amenorrhea. Cancer Treat. Rep. 1986;70:659–661
  34. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, et al.  Acute promyelocytic leukemia following mitoxantrone as a single agent for the treatment of multiple sclerosis. Leukemia. 1998;12:441–442
  35. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim. Biophys. Acta. 1998;1400:233–255
  36. Ghalie R, Mauch E, Edan G, Hartung H, Gonsette RE, Eisenmann S, et al. A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis. Mult. Sclerosis. 2002;8:441–445
  37. Edan G, Brochet B, Brassat D, Clanet M, Clavelou P, Confavreux C, et al.  Safety profile of mitoxantrone in a cohort of 802 multiple sclerosis patients. Neurology. 2002;58:A168
  38. Schroth WS, Tenner SM, Rappaport BA, Mani R. Multiple sclerosis as a cause of atrial fibrillation and electrocardiographic changes. Arch. Neurol. 1992;49:422–424
  39. Ziaber J, Chmielewski H, Dryjanski T, Goch JH. Evaluation of myocardial muscle functional parameters in patients with multiple sclerosis. Acta Neurol. Scand. 1997;95:335–337
  40. Drouin E, Nataf S, Lande G, Louboutin JP. Abnormalities of cardiac repolarization in multiple sclerosis: relationship with a model of allergic encephalomyelitis in rat. Muscle Nerve. 1998;21:940–942
  41. Olindo S, Guillon B, Hélias J, Philibert B, Magne C, Fève JR. Decrease in heart ventricular ejection fraction during multiple sclerosis. Eur. J. Neurol. 2002;9:287–291
  42. Beer M, Sandstede J, Weilbach F, et al.  Cardiac metabolism and function in patients with multiple sclerosis: a combined 31P-MR-spectroscopy and MRI study. RoFo. Fortschr. Geb. Rontgenstrahlen Neuen Bildgeb. Verfahr. 2001;173:399–404
  43. Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The provincial systemic treatment disease site group. Cancer Prev. Control. 1999;3:145–159
  44. Weiss G, Loyevsky M, Gordeuk VR. Dexrazoxane (ICRF-187). Gen. Pharmacol. 1999;32:155–158
  45. Mikol DD, Bernitsas E. Novantrone plus dexrazoxane therapy in multiple sclerosis patients: a safety and tolerability pilot study. Mult. Scler. 2001;7(Suppl. 1):S14; [0–27]
  46. Malisza KL, Hasinoff BB. Doxorubicin reduces the iron (III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals. Arch. Biochem. Biophys. 1995;316:680–688
  47. Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. 1992;52:194–201
  48. Shipp NG, Dorr RT, Alberts DS, Dawson BV, Hendrix M. Characterization of experimental mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res. 1993;53:550–556
  49. Herman EH, Zhang J, Rifai N, et al.  The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother. Pharmacol. 2001;48:297–304
  50. Budman DR, Calabro A, Kreis W. In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?. Leukemia. 2001;15:1517–1520
  51. Weilbach FX, Toyka KV, Gold R. Combination therapy with the iron chelator dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis in lewis rats. Rev. Neurol. 2000;156(Suppl. 3):3S127; [P175]
  52. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Safety. 2000;22:263–302
  53. Keefe DL. Anthracycline-induced cardiomyopathy. Semin. Oncol. 2001;28(Suppl. 12):2–7
  54. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, et al.  Disease modifying therapies in multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169–178
  55. Krapcho AP, Petry ME, Getahun Z, et al.  6,9-Bis[(aminoalkyl)amino]benzo[g] isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J. Med. Chem. 1994;37:828–837
  56. Dubois B, Gonsette R, Dillen C, Billiau A. Efficacy of a novel non-cardiotoxic aza-anthracenedione (BBR27781) in acute EAE. Mult. Scler. 2001;7(Suppl. 1):S20; [P-010]

PII: S0022-510X(02)00335-0

Journal of the Neurological Sciences
Volume 206, Issue 2 , Pages 203-208 , 15 February 2003

Article Tools